Abstract
The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Current Pharmaceutical Design
Title:The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Volume: 27 Issue: 23
Author(s): Nikolaos Sofikitis*, Aris Kaltsas, Fotios Dimitriadis, Jens Rassweiler, Nikolaos Grivas, Athanasios Zachariou, Apostolos Kaponis, Panagiota Tsounapi, Napoleon Paterakis, Andreas Karagiannis, Sotirios Skouros, Ioannis Giannakis, Ioannis Champilomatis, Minas Paschopoulos, Diamantis Daphnis, Ioannis Giakoumakis, Melinda R.Gabales, Jo Ben M. Chua, Pedro L. Lantin III, Charalampos Mamoulakis and Atsushi Takenaka
Affiliation:
- Department of Urology, Ioannina University School of Medicine, Ioannina,Greece
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Abstract: The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Export Options
About this article
Cite this article as:
Sofikitis Nikolaos *, Kaltsas Aris , Dimitriadis Fotios , Rassweiler Jens , Grivas Nikolaos , Zachariou Athanasios , Kaponis Apostolos , Tsounapi Panagiota , Paterakis Napoleon , Karagiannis Andreas , Skouros Sotirios , Giannakis Ioannis , Champilomatis Ioannis , Paschopoulos Minas , Daphnis Diamantis , Giakoumakis Ioannis , R.Gabales Melinda , M. Chua Ben Jo , Lantin III L. Pedro, Mamoulakis Charalampos and Takenaka Atsushi , The Effect of PDE5 Inhibitors on the Male Reproductive Tract, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612826666200226121510
DOI https://dx.doi.org/10.2174/1381612826666200226121510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Management of Acute Coronary Syndromes in Patients with Renal Insufficiency
Current Cardiology Reviews Inflammation, Atrial Fibrillation and Cardiac Surgery: Current Medical and Invasive Approaches for the Treatment of Atrial Fibrillation
Current Pharmaceutical Design Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Protease Inhibitors in the Clinic
Medicinal Chemistry Mechanisms of Vascular Calcification and Associated Diseases
Current Pharmaceutical Design Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets Vasoconstrictor Therapy for Hepatorenal Syndrome in Liver Cirrhosis
Current Pharmaceutical Design Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Lipid Behavior in Metabolic Syndrome Pathophysiology
Current Diabetes Reviews Synthesis, Formulation and Analytical Method Validation of Rutin Derivative
Letters in Drug Design & Discovery Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies
Current Drug Abuse Reviews Predictor Role of Intimate Domestic Violence During Pregnancy and Mental Health in Maternal Competency with Moderating Role of Motherinfant Attachment: A Structural Equation Model
Current Women`s Health Reviews Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor)
Current Molecular Medicine Mechanisms of Salt-Sensitive Hypertension
Current Hypertension Reviews Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer’s Disease
Current Alzheimer Research Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design